Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capio in conjunction with its acquisition of PR Vård
Mandate

Vinge advises Capio in conjunction with its acquisition of PR Vård

March 31, 2022 Employment and Benefits IT, Telecommunications and Outsourcing EU, Competition and Regulatory M&A Public Procurement

Vinge is advising Capio in connection with its acquisition of all shares in PR Vård Hemsjukvåd AB and PR Vård Mottagning AB.

PR Vård conducts home healthcare operations in five out of eight primary health areas in Stockholm as well as one surgery for children and young people and one healthcare surgery in Södermalm. PR Vård has 600 employees and performs approximately 1 million home healthcare visits per year. The acquisition is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Anders Strid and Jenny Sandlund (project manager), Victoria Gunnerek (public procurement), Adam Löwenstein (tenancy law), Alexander Lindeberg (IT/GDPR), Anna Ståhlklo (employment law), Fredrik Löwenklou (M&A) as well as Anna Palmérus (competition law).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026